Please enable JavaScript to continue using this application.

Compare $EVMN vs $PLX | Chartloom

Compare

$EVMN vs $PLX

Evommune Inc · Protalix Biotherapeutics Inc

EVMN

Evommune Inc

PLX

Protalix Biotherapeutics Inc

Compare $EVMN vs $PLX

Comparing Evommune Inc and Protalix Biotherapeutics Inc

EVMNEvommune Inc

PLXProtalix Biotherapeutics Inc

EVMNEvommune Inc

Market cap

$225M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-63.9%

52W performance

-69.1%

FCF yield

-55.4%

PLXProtalix Biotherapeutics Inc

Market cap

$224M

P/E (TTM)

12.11x

Forward P/E (NTM)

—

Forward P/S (NTM)

3.56x

Rev growth (TTM)

30.1%

YTD performance

59.8%

52W performance

8.2%

FCF yield

3.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

EVMN

PLX

Detailed metrics comparison

EVMN

Evommune Inc

PLX

Protalix Biotherapeutics Inc

Market Cap

EVMN$225M

PLX$224M

Enterprise Value

EVMN$166M

PLX$197M

Price

EVMN$6.25

PLX$2.78

P/E Ratio

EVMNN/A

PLX12.11x

P/S Ratio

EVMN14.07x

PLX2.78x

EV/Sales

EVMN10.38x

PLX2.44x

EV/EBITDA

EVMN0.00x

PLX7.37x

P/B Ratio

EVMN0.90x

PLX3.06x

P/FCF Ratio

EVMNN/A

PLX29.21x

EV/FCF

EVMN-1.33x

PLX25.63x

PEG Ratio

EVMNN/A

PLX0.06x

Forward P/E (NTM)

EVMNN/A

PLXN/A

Forward P/S (NTM)

EVMNN/A

PLX3.56x

Revenue (TTM)

EVMN$16M

PLX$81M

Revenue Growth (YoY)

EVMNN/A

PLX30.1%

Forward Rev Growth

EVMN881.5%

PLX-19.1%

Gross Margin (TTM)

EVMN0.0%

PLX69.2%

Operating Margin (TTM)

EVMN0.0%

PLX28.9%

EBITDA Margin (TTM)

EVMN-1097.9%

PLX30.8%

Net Margin (TTM)

EVMN-943.2%

PLX23.5%

FCF Margin (TTM)

EVMN-779.8%

PLX9.5%

Net Income (TTM)

EVMN$-151M

PLX$19M

FCF (TTM)

EVMN$-125M

PLX$8M

EPS (TTM)

EVMN-$4.18

PLX$0.23

ROE (TTM)

EVMN-4676.0%

PLX31.6%

ROA (TTM)

EVMN-4337.0%

PLX20.1%

ROIC (TTM)

EVMN-4661.0%

PLX31.6%

Cash

EVMN$60M

PLX$27M

Debt

EVMN$952K

PLX$0

Net Cash/Debt

EVMN$59M

PLX$27M

Current Ratio (TTM)

EVMN11.68x

PLX2.94x

Quick Ratio (TTM)

EVMN11.48x

PLX1.91x

Debt/Equity (TTM)

EVMN0.00x

PLX0.00x

Debt/Assets (TTM)

EVMN0.0%

PLX0.0%

Interest Coverage (TTM)

EVMNN/A

PLXN/A

Net Debt/EBITDA (TTM)

EVMN0.00x

PLX0.00x

Beta

EVMN0.62

PLX-0.05

52W Performance

EVMN-69.1%

PLX8.2%

YTD Performance

EVMN-63.9%

PLX59.8%

% from 52W High

EVMN-81.2%

PLX-12.9%

% from 52W Low

EVMN3.8%

PLX73.7%

Asset Turnover (TTM)

EVMN0.00x

PLX0.85x

FCF Yield (TTM)

EVMN-55.4%

PLX3.4%

Earnings Yield (TTM)

EVMN-67.0%

PLX8.5%

Dividend Yield (TTM)

EVMNN/A

PLXN/A

Rule of 40

EVMN-779.8

PLX39.7

EV/GP/RG

EVMNN/A

PLXN/A

Ticker research

View EVMN research View PLX research

Metric	EVMN Evommune Inc	PLX Protalix Biotherapeutics Inc
Market & Valuation
Market Cap	$225M	$224M
Enterprise Value	$166M	$197M
Price	$6.25	$2.78
P/E Ratio	N/A	12.11x
P/S Ratio	14.07x	2.78x
EV/Sales	10.38x	2.44x
EV/EBITDA	0.00x	7.37x
P/B Ratio	0.90x	3.06x
P/FCF Ratio	N/A	29.21x
EV/FCF	-1.33x	25.63x
PEG Ratio	N/A	0.06x
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	3.56x
Revenue & Growth
Revenue (TTM)	$16M	$81M
Revenue Growth (YoY)	N/A	30.1%
Forward Rev Growth	881.5%	-19.1%
Profitability
Gross Margin (TTM)	0.0%	69.2%
Operating Margin (TTM)	0.0%	28.9%
EBITDA Margin (TTM)	-1097.9%	30.8%
Net Margin (TTM)	-943.2%	23.5%
FCF Margin (TTM)	-779.8%	9.5%
Net Income (TTM)	$-151M	$19M
FCF (TTM)	$-125M	$8M
EPS (TTM)	-$4.18	$0.23
ROE (TTM)	-4676.0%	31.6%
ROA (TTM)	-4337.0%	20.1%
ROIC (TTM)	-4661.0%	31.6%
Financial Health
Cash	$60M	$27M
Debt	$952K	$0
Net Cash/Debt	$59M	$27M
Current Ratio (TTM)	11.68x	2.94x
Quick Ratio (TTM)	11.48x	1.91x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.62	-0.05
52W Performance	-69.1%	8.2%
YTD Performance	-63.9%	59.8%
% from 52W High	-81.2%	-12.9%
% from 52W Low	3.8%	73.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.85x
FCF Yield (TTM)	-55.4%	3.4%
Earnings Yield (TTM)	-67.0%	8.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-779.8	39.7
EV/GP/RG	N/A	N/A
Ticker research	View EVMN research	View PLX research

Valuation

P/E Ratio

PLX

12.11x

P/S Ratio

PLX

2.78x

EVMN

14.07x

EV/FCF

EVMN

-1.33x

PLX

25.63x

Growth & revenue

Revenue Growth TTM

PLX

30.1%

Forward Revenue Growth

EVMN

881.5%

PLX

-19.1%

Profitability & performance

Gross Margin

PLX

69.2%

EVMN

0.0%

ROE

PLX

31.6%

EVMN

-4676.0%

FCF Yield %

PLX

3.4%

EVMN

-55.4%

52-Week Performance

PLX

8.2%

EVMN

-69.1%

Detailed metrics comparison

EVMN

Evommune Inc

PLX

Protalix Biotherapeutics Inc

Market Cap

EVMN$225M

PLX$224M

Enterprise Value

EVMN$166M

PLX$197M

Price

EVMN$6.25

PLX$2.78

P/E Ratio

EVMNN/A

PLX12.11x

P/S Ratio

EVMN14.07x

PLX2.78x

EV/Sales

EVMN10.38x

PLX2.44x

EV/EBITDA

EVMN0.00x

PLX7.37x

P/B Ratio

EVMN0.90x

PLX3.06x

P/FCF Ratio

EVMNN/A

PLX29.21x

EV/FCF

EVMN-1.33x

PLX25.63x

PEG Ratio

EVMNN/A

PLX0.06x

Forward P/E (NTM)

EVMNN/A

PLXN/A

Forward P/S (NTM)

EVMNN/A

PLX3.56x

Revenue (TTM)

EVMN$16M

PLX$81M

Revenue Growth (YoY)

EVMNN/A

PLX30.1%

Forward Rev Growth

EVMN881.5%

PLX-19.1%

Gross Margin (TTM)

EVMN0.0%

PLX69.2%

Operating Margin (TTM)

EVMN0.0%

PLX28.9%

EBITDA Margin (TTM)

EVMN-1097.9%

PLX30.8%

Net Margin (TTM)

EVMN-943.2%

PLX23.5%

FCF Margin (TTM)

EVMN-779.8%

PLX9.5%

Net Income (TTM)

EVMN$-151M

PLX$19M

FCF (TTM)

EVMN$-125M

PLX$8M

EPS (TTM)

EVMN-$4.18

PLX$0.23

ROE (TTM)

EVMN-4676.0%

PLX31.6%

ROA (TTM)

EVMN-4337.0%

PLX20.1%

ROIC (TTM)

EVMN-4661.0%

PLX31.6%

Cash

EVMN$60M

PLX$27M

Debt

EVMN$952K

PLX$0

Net Cash/Debt

EVMN$59M

PLX$27M

Current Ratio (TTM)

EVMN11.68x

PLX2.94x

Quick Ratio (TTM)

EVMN11.48x

PLX1.91x

Debt/Equity (TTM)

EVMN0.00x

PLX0.00x

Debt/Assets (TTM)

EVMN0.0%

PLX0.0%

Interest Coverage (TTM)

EVMNN/A

PLXN/A

Net Debt/EBITDA (TTM)

EVMN0.00x

PLX0.00x

Beta

EVMN0.62

PLX-0.05

52W Performance

EVMN-69.1%

PLX8.2%

YTD Performance

EVMN-63.9%

PLX59.8%

% from 52W High

EVMN-81.2%

PLX-12.9%

% from 52W Low

EVMN3.8%

PLX73.7%

Asset Turnover (TTM)

EVMN0.00x

PLX0.85x

FCF Yield (TTM)

EVMN-55.4%

PLX3.4%

Earnings Yield (TTM)

EVMN-67.0%

PLX8.5%

Dividend Yield (TTM)

EVMNN/A

PLXN/A

Rule of 40

EVMN-779.8

PLX39.7

EV/GP/RG

EVMNN/A

PLXN/A

Ticker research

View EVMN research View PLX research

Metric	EVMN Evommune Inc	PLX Protalix Biotherapeutics Inc
Market & Valuation
Market Cap	$225M	$224M
Enterprise Value	$166M	$197M
Price	$6.25	$2.78
P/E Ratio	N/A	12.11x
P/S Ratio	14.07x	2.78x
EV/Sales	10.38x	2.44x
EV/EBITDA	0.00x	7.37x
P/B Ratio	0.90x	3.06x
P/FCF Ratio	N/A	29.21x
EV/FCF	-1.33x	25.63x
PEG Ratio	N/A	0.06x
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	3.56x
Revenue & Growth
Revenue (TTM)	$16M	$81M
Revenue Growth (YoY)	N/A	30.1%
Forward Rev Growth	881.5%	-19.1%
Profitability
Gross Margin (TTM)	0.0%	69.2%
Operating Margin (TTM)	0.0%	28.9%
EBITDA Margin (TTM)	-1097.9%	30.8%
Net Margin (TTM)	-943.2%	23.5%
FCF Margin (TTM)	-779.8%	9.5%
Net Income (TTM)	$-151M	$19M
FCF (TTM)	$-125M	$8M
EPS (TTM)	-$4.18	$0.23
ROE (TTM)	-4676.0%	31.6%
ROA (TTM)	-4337.0%	20.1%
ROIC (TTM)	-4661.0%	31.6%
Financial Health
Cash	$60M	$27M
Debt	$952K	$0
Net Cash/Debt	$59M	$27M
Current Ratio (TTM)	11.68x	2.94x
Quick Ratio (TTM)	11.48x	1.91x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.62	-0.05
52W Performance	-69.1%	8.2%
YTD Performance	-63.9%	59.8%
% from 52W High	-81.2%	-12.9%
% from 52W Low	3.8%	73.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.85x
FCF Yield (TTM)	-55.4%	3.4%
Earnings Yield (TTM)	-67.0%	8.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-779.8	39.7
EV/GP/RG	N/A	N/A
Ticker research	View EVMN research	View PLX research